Drug combination boosts survival rate in head and neck cancers

	Tweet

Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. The findings will be presented at the American Society of Clinical Oncology’s annual meeting.

Previous studies have shown that using combination chemotherapy of cisplatin and 5-fu yields a 25 to 50 percent rate of complete pathological responses (the tumor disappeared). Robert Haddad, MD, and his colleagues found that adding the drug docetaxel (Taxotere) to the cisplatin and 5-fu regimen significantly increased the complete pathological response rate to 89 percent.

The data (Abstract 5511) will be presented as a poster discussion session on Saturday, May 14, at 1 p.m., Level 4, 414.

Using data obtained from treating 72 patients with locally advanced squamous cell carcinoma of the head and neck, the researchers project that the three-drug combination would result in a 95 percent two-year survival rate and a 90 percent five-year survival rate. The majority of these patients have stage IV disease.

“These results are very encouraging and in all likelihood will translate into a significantly more effective treatment for patients with advanced head and neck cancer,” says Haddad. “This patient population historically has had a poor prognosis, but, given these findings, the outlook is more hopeful.”

The drug combination is given for three cycles as an initial treatment, known as induction chemotherapy, to shrink tumors prior to several weeks of intense treatment with additional chemotherapy given along with radiation. This “sequential therapy” has brought about the most successful results in patients with these stubborn cancers. Cancers of the head and neck are diagnosed in more than 40,000 people in the United States each year, with about 7,200 deaths.

Based on recent results of Phase III trials of the therapy and on the new data, Haddad, who is also an assistant professor at Harvard Medical School, and his colleagues propose that the three-drug combination be used as the new platform when using induction chemotherapy.

RELATED STORIES:
Chemotherapy Complications Greater than Previously Estimated   Marriage tied to better bladder cancer survival   Cancer gene therapy from camels   New DNA technique leads to a breakthrough in child cancer research   Cancer seen killing 1.3 million EU citizens in 2012   Deactivating a cancer growth promoter   Controlling for size may also prevent cancer   New era in cancer prevention   U.S. experts weigh how to reduce radiation from scans   Study Shows Fish Oil Does Not Prevent Cancer and May Increase Risk in Women   New Markers of Prognosis for Cancer Therapies Highlighted   Novel therapy may prove effective in treatment of 30 percent of cancers   Smokeless tobacco ups risk of pancreatic cancer   Nanoparticles may enhance cancer therapy   Persons Who Survive Cancer More Likely to be Unemployed   New drug slows advanced kidney cancer   U.S. cancer diagnoses will jump 45 percent by 2030   Using a molecular switch to turn on cancer vaccines   How sunlight causes skin cells to turn cancerous   Lilly brain cancer drug promising in small study   Immunotherapy for tumors key topic at cancer meeting   Low Molecular Weight Heparin Use in Cancer Treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]